TP53 and cancer: The TP73 gene has attracted incredible attention for therapeutic cancer management mainly because it can mimic and/or surrogate for p53 oncosuppressive functions, whereas unlike p53, it is rarely mutated in cancer, a fact that renders this targeting unbiased from intra- and inter-tumoral mutational heterogeneity (Logotheti et al., 2019).